July 30, 2026- Baxter International Inc. reported results for the second quarter of 2026.
Second-Quarter 2026 Companywide Financial Results
Unless otherwise noted, all financial results reflect continuing operations and exclude Baxter’s former Kidney Care business, which is reported as discontinued operations.
- Worldwide sales in the second quarter totaled approximately $2.96 billion, increasing 5% on both a reported and organic basis.
- U.S. sales in the second quarter totaled approximately $1.6 billion, increasing 4% on both a reported and organic basis.
- International sales in the second quarter totaled approximately $1.4 billion, increasing 7% on a reported basis and 5% on an organic basis.
- On a U.S. GAAP basis, net income totaled $135 million, or $0.26 per diluted share.
- On an adjusted basis, net income in the second quarter was $0.56 per diluted share, decreasing 5% from the prior year. As expected, results reflect the roll through of higher-cost inventory produced at the end of 2025, as well as an unfavorable comparison to the prior year related to the reclassification of certain functional costs from SG&A to cost of sales. These impacts were partially offset by a $0.11 per diluted share benefit related to an IEEPA4 tariff refund.
- Free cash flow was $181 million in the second quarter and totaled $257 million in the first half of the year.
Please see the attached schedules accompanying this press release for additional details on sales performance in the quarter, including breakouts by Baxter’s segments.